• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Hungary Pharmaceuticals & Healthcare Report Q4 2006 - Product Image

Hungary Pharmaceuticals & Healthcare Report Q4 2006

  • ID: 461341
  • February 2007
  • Region: Hungary
  • 68 pages
  • Business Monitor International


  • BMI Forecast Modelling
  • Eli Lilly
  • Gedeon Richter
  • Krka
  • MORE

The Hungary Pharmaceuticals & Healthcare Report provides independent forecasts and competitive intelligence on Hungarys pharmaceuticals & healthcare industry.

The Hungarian pharmaceutical market has been rocked in recent months by government-imposed healthcare reforms that seek to contain costs. Numerous stakeholders have been affected by the changes, particularly drugmakers, which are dismayed at the state’s plan to reduce their profits. Nevertheless, the reforms may increase consumption of medicines, particularly higher-priced, innovative products.
Accordingly, we are maintaining our projections for drug market expenditure, which is expected to reach US$4.9bn by 2010. To the likely consternation of the average citizen, Hungary’s government has approved a healthcare reform bill that will introduce fees for seeing a doctor and define service packages in an effort to contain costs. The legislation is part of the country’s efforts to reform its inefficient and expensive healthcare system, which has contributed to huge overspending of the budget. While the fees may prove unpopular, it is thought that measures such as these are vital to maintain the necessary READ MORE >


  • BMI Forecast Modelling
  • Eli Lilly
  • Gedeon Richter
  • Krka
  • MORE

Executive Summary
Hungary Pharmaceuticals & Healthcare Industry SWOT
Hungary Political SWOT
Hungary Economic SWOT
Hungary Business Environment SWOT
Business Environment Rankings
Central & Eastern European Region
Table: Central & Eastern Europe Pharmaceuticals Business Environment Ranking
Business Environment Ranking
Economics - Long-Term Risk
Politics - Long-Term Risk
Regulatory Barriers
Domestic Sector Threat
Market Growth Potential
Market Size Ranking
Market Overview
Table: Leading Pharmaceutical Companies By Ownership
Regulatory Regime
Healthcare Reforms
Intellectual Property Regime
Pricing & Reimbursement Issues
Epidemiological Trends
Biotechnology Sector
Table: Hungarian Biotechnology At A Glance (FY2005)
CRO Sector
Industry Forecast Scenario
Overall Market Forecast
Table: Drug Market Indicator Forecasts 2004-2010
Key Growth Factors – Industry
Table: Health Expenditure Indicator Forecasts 2004-2010
Key Growth Factors – Macroeconomic
Table: Nominal And Real GDP
OTC Market Forecast
Table: OTC Market Indicator Forecasts 2004-2009
Prescription Market Forecast
Table: Prescription Drug Market Forecasts 2004-2010
Generics & Branded Markets Forecast
Table: Generics And Branded Market Indicator Forecasts 2004-2010
Export/Import Forecasts
Table: Import/Export Market Forecasts 2004-2010
Key Risks To BMI’s Forecast Scenario
Country Snapshot: Hungary Demographic Data
Section 1: Population
Table: Demographic Indicators (2005)
Table: Rural/Urban Breakdown
Section 2: Education & Healthcare
Table: Education
Table: Healthcare: Vital Statistics
Table: Healthcare: Expenditure
Section 3: Labour Market And Spending Power
Table: Employment Indicators
Table: Consumption and Stratification
Table: Wages per year
Competitive Landscape
Company Monitor
Egis Pharmaceuticals (Servier)
Eli Lilly
Gedeon Richter
BMI Forecast Modelling
How We Generate Our Industry Forecasts
Technical Process
Pharmaceuticals Industry
Appendix: Regional Demographic Data
Wages (ave labour force per annum), US$ PPP
Household Spending Per Capita, US$
Private Consumption Per Capita, US$ PPP
Market Size, GDP, US$bn

Egis Pharmaceuticals (Servier)
Eli Lilly
Gedeon Richter
BMI Forecast Modelling

Note: Product cover images may vary from those shown


Our Clients

Our clients' logos